Good progress. Number of patients recruited is somewhere between...

First 7 Last

Share
Profile

Follow
pfeifer1982

1,300 Posts.

3959

25/10/24

10:20

Post #: 76296174
Share

Originally posted by KrushingIt: ↑

Good progress!

According to clinicaltrials.gov, up to 32 patients will be enrolled. So if 20 more patients will be dosed during the dose expansion cohort per today's ASX announcement, that means 12 patients have already been dosed - with no major side effects.

We should get some prelim data by the end of the year. This may coincide with the ASH conference (the premier event in malignant and non-malignant hematology) in the US in December. Given the strong efficacy signals and two complete responses in the Case Western CORE NK AML Trial using...this bodes well for this trial!! (albeit different eligibility criteria and treatment regime)

https://clinicaltrials.gov/study/NCT05834244?term=NCT05834244&rank=1

Expand

Good progress. Number of patients recruited is somewhere between 6-12 at this stage:

"Trial design: The dose escalation phase will enroll a maximum of 12 patients at 2 dose levels to establish a recommended phase 2 dose (RP2D) using a BOIN design. The dose expansion will enroll up to 20 patients at the RP2D ( Fig. 1)."

https://ashpublications.org/blood/article/142/Supplement%201/4863/505848/Azacitidine-Venetoclax-and-Allogeneic-NK-Cells-in

CHM Price at posting: 1.0¢ Sentiment: Buy Disclosure: Held
10 Upvote

0 Great analysis

Reply

Top Stories

ASX Market Close: Bourse spins in circles as Israel-Iran conflict weighs | June 17, 2025

VBX Ltd jumps 15% on ASX debut as newest Oz bauxite player

RCE

Recce locks in $30M to boost commercialisation across ASEAN region

Listen: HotCopper Wire Podcast 013 - They changed the IPO rules (and that's a good thing)

MEM

Many are concerned about global falling birthrates. This diverse stock has solutions

First 7 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 0.4¢		Change 0.000(0.00%)		Mkt cap ! $8.060M

Open	High	Low	Value	Volume
0.4¢	0.4¢	0.4¢	$100	25K

Buyers (Bids)

No.	Vol.	Price($)
28	21874000	0.4¢

Sellers (Offers)

Price($)	Vol.	No.
0.5¢	19510638	27

View Market Depth

No.	Vol.	Price($)
28	21874000	0.004
37	23631939	0.003
15	13500507	0.002
9	49600000	0.001
0	0	0.000

Price($)	Vol.	No.
0.005	19510638	27
0.006	23500718	17
0.007	4700000	4
0.008	8542434	6
0.009	2767672	5

Last trade - 15.25pm 17/06/2025 (20 minute delay)

CHM (ASX) Chart

Good progress. Number of patients recruited is somewhere between...

ASX Market Close: Bourse spins in circles as Israel-Iran conflict weighs | June 17, 2025

VBX Ltd jumps 15% on ASX debut as newest Oz bauxite player

Recce locks in $30M to boost commercialisation across ASEAN region

Listen: HotCopper Wire Podcast 013 - They changed the IPO rules (and that's a good thing)

Many are concerned about global falling birthrates. This diverse stock has solutions

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Good progress. Number of patients recruited is somewhere between...

Top Stories

ASX Market Close: Bourse spins in circles as Israel-Iran conflict weighs | June 17, 2025

VBX Ltd jumps 15% on ASX debut as newest Oz bauxite player

Recce locks in $30M to boost commercialisation across ASEAN region

Listen: HotCopper Wire Podcast 013 - They changed the IPO rules (and that's a good thing)

Many are concerned about global falling birthrates. This diverse stock has solutions

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News